Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $989000.0.

  • Sangamo Therapeutics' Depreciation & Amortization (CF) fell 1880.13% to $989000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 2592.53%. This contributed to the annual value of $5.1 million for FY2024, which is 6617.88% down from last year.
  • According to the latest figures from Q3 2025, Sangamo Therapeutics' Depreciation & Amortization (CF) is $989000.0, which was down 1880.13% from $993000.0 recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' Depreciation & Amortization (CF) registered a high of $5.5 million during Q3 2023, and its lowest value of $989000.0 during Q3 2025.
  • For the 5-year period, Sangamo Therapeutics' Depreciation & Amortization (CF) averaged around $2.4 million, with its median value being $2.2 million (2021).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 8786.76% in 2021, then tumbled by 7782.63% in 2024.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Depreciation & Amortization (CF) stood at $2.8 million in 2021, then rose by 20.95% to $3.3 million in 2022, then plummeted by 44.3% to $1.9 million in 2023, then tumbled by 33.35% to $1.2 million in 2024, then decreased by 20.31% to $989000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $989000.0 for Q3 2025, versus $993000.0 for Q2 2025 and $1.0 million for Q1 2025.